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Abstract
Background: Preclinical research implicates dopaminergic and noradrenergic mechanisms in mediating the reinforcing
effects of drugs of abuse, including cocaine. The objective of this study was to evaluate the impact of treatment with the
noradrenergic a1 receptor antagonist doxazosin on the positive subjective effects of cocaine.
Methods: Thirteen non-treatment seeking, cocaine-dependent volunteers completed this single-site, randomized, placebo-
controlled, within-subjects study. In one study phase volunteers received placebo and in the other they received doxazosin,
with the order counterbalanced across participants. Study medication was masked by over-encapsulating doxazosin tablets
and matched placebo lactose served as the control. Study medication treatment was initiated at 1 mg doxazosin or
equivalent number of placebo capsules PO/day and increased every three days by 1 mg. After receiving 4 mg doxazosin or
equivalent number of placebo capsules participants received masked doses of 20 and 40 mg cocaine IV in that order with
placebo saline randomly interspersed to maintain the blind.
Results: Doxazosin treatment was well tolerated and doxazosin alone produced minimal changes in heart rate and blood
pressure. During treatment with placebo, cocaine produced dose-dependent increases in subjective effect ratings of ‘‘high’’,
‘‘stimulated’’, ‘‘like cocaine’’, ‘‘desire cocaine’’, ‘‘any drug effect’’, and ‘‘likely to use cocaine if had access’’ (p,.001).
Doxazosin treatment significantly attenuated the effects of 20 mg cocaine on ratings of ‘‘stimulated’’, ‘‘like cocaine’’, and
‘‘likely to use cocaine if had access’’ (p,.05). There were trends for doxazosin to reduce ratings of ‘‘stimulated’’, ‘‘desire
cocaine’’, and ‘‘likely to use cocaine if had access’’ (p,.10).
Conclusions: Medications that block noradrenergic a1 receptors, such as doxazosin, may be useful as treatments for cocaine
dependence, and should be evaluated further.
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Introduction
A great deal of research aimed at developing treatments for
cocaine dependence has focused on agents that directly or
indirectly alter functioning of dopaminergic systems, as dopamine
(DA) is known to play an important role in mediating cocaine’s
reinforcing effects [1]. Progress has been limited, however, as DA
antagonists are aversive and non-specifically disrupt behavior [2].
Most direct DA agonists have proven ineffective as treatments for
cocaine dependence [3], and indirect DA agonists such as
amphetamine or methamphetamine, while effective for reducing
cocaine use [4,5], have substantial abuse liability that limits their
utility [6].
Genetic and pharmacological evidence has implicated norad-
renergic mechanisms in mediating the effects of cocaine and other
stimulants [7]. For example, animals which do not express the
noradrenergic a1 receptor (a1R) are insensitive to the locomotor
activating effects of cocaine and amphetamine [8,9], and
treatment with the noradrenergic a1R antagonist prazosin blocks
both cocaine-induced locomotor activation [10,11] and cocaine-
induced reinstatement of extinguished cocaine self-administration
in rats [12].
Prazosin is the prototypical a1R antagonist. Prazosin has an
elimination half-life of 2-3 hours in humans [13], and this limits its
potential clinical utility because most patients cannot reliably
adhere to dosing regimens that require dosing throughout the day.
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30854Doxazosin is a newer a1R antagonist with an elimination half-life
of 22 hours in humans [14], allowing once-daily dosing. Although
early reports indicated that doxazosin had poor brain penetration
[15,16], the side-effects of doxazosin, which include fatigue,
dizziness, and somnolence, suggest that doxazosin acts centrally.
We assessed the impact of doxazosin treatment on cocaine’s
effects using a double-blind, placebo-controlled, within-subjects
design in non-treatment-seeking, cocaine-dependent volunteers.
We hypothesized that doxazosin treatment would attenuate the
subjective effects of cocaine.
Materials and Methods
Participants
Non-treatment-seeking, cocaine-dependent participants were
recruited through advertisements and were paid for their
participation. They received $50 per day for inpatient components
of the study and received a $100 completion bonus. All
participants met DMS-IV criteria for cocaine dependence, were
between 18 and 55 years old, had a history of using cocaine by the
smoked or IV route, and normal laboratory evaluation, ECG, and
Figure 1. CONSORT Flowchart. Participant flowchart.
doi:10.1371/journal.pone.0030854.g001
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epilepsy, dependence on drugs other than cocaine and nicotine,
inability to detect effects of cocaine, or the presence of any other
axis I psychiatric disorder. Serious medical conditions such as
heart disease, AIDS, and asthma were also exclusionary.
Concomitant use of psychotropic medications or medications
affecting blood pressure was not allowed. This study was approved
by the institutional review board of the Baylor College of Medicine
and all participants gave informed consent.
Assessments
Clinical diagnosis was determined using the MINI [17]. Mood
was assessed using the Beck Depression Inventory [18]. Heart rate
and blood pressure were measured frequently throughout the
study and at several time points following cocaine dosing.
Subjective effects of cocaine were measured using visual-analogue
scales anchored at 0 (no effect) and 100 (most ever). Ratings were
obtained for ‘‘high’’, ‘‘any drug effects’’, ‘‘stimulated’’, ‘‘good
effects’’, ‘‘like cocaine’’, ‘‘bad effects’’, ‘‘anxious’’, ‘‘desire co-
caine’’, and ‘‘likely to use cocaine if had access’’. Subjective effects
ratings were obtained prior to cocaine dosing and at 5 min
intervals until 55 min after dosing. Heart rate and blood pressure
measures were also collected at the same time points.
Medications
Doxazosin 1 mg tablets were purchased commercially from
Green Park Pharmacy, Houston TX. Doxazosin was over-
encapsulated to mask study medication treatment and encapsu-
lated placebo lactose served as the control. Sterile cocaine HCl for
human use was provided by NIDA’s medication supply program
by RTI International, Research Triangle Park, NC. Sterile saline
was used to dilute the cocaine to the desired concentration and
also served as the placebo for cocaine.
Study Design
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The study employed a within-subjects, double-blind,
placebo-controlled design. The order in which participants
received doxazosin and placebo was counterbalanced across
participants. At least 2 weeks separated study episodes to allow
medication wash-out. After screening to assure that participants
met inclusion and exclusion criteria, participants were enrolled
and housed on the Research Commons of the Michael E.
DeBakey VA Medical Center. Participants were monitored closely
while inpatient and intermittent UAs were performed to ensure
that participants remained abstinent for substances not adminis-
tered as part of the protocol. Participants were discharged from the
hospital between the study episodes. Study medication was started
at one capsule per day in the morning and increased by one
capsule every three days until participants reached four capsules
per day. Resting and orthostatic blood pressure measurements
were monitored frequently, as doxazosin can cause hypotension,
especially after increases in the dose.
Cocaine Dosing
When participants reached 4 mg doxazosin/placebo/d (Day 10
of study medication treatment), participants received cocaine (20
and 40 mg, IV) in ascending order with a dose of saline randomly
interspersed to maintain the blind. Two of the three doses were
given in the morning, separated by 1 h. The third dose was given
in the afternoon, several hours after the previous dose. The three
doses were sufficiently separated in time to allow effects to
completely dissipate between doses [19]. Participants were
monitored and discharged from the hospital when stable, generally
after 6–8 h.
Outcomes
The primary outcome was the impact of doxazosin treatment
on the cardiovascular and subjective effects of cocaine. We also
assessed the tolerability of doxazosin treatment alone in this
population, with particular attention to effects of doxazosin
treatment on blood pressure. We planned on enrolling 15
participants with the goal of obtaining at least 10 completers.
Table 1. Demographic Characteristics.
Cocaine Users
(N=13)
Gender (N)
Male 12 (92%)
Female 1 (8%)
Ethnicity (N)
Caucasian 3 (23%)
Hispanic 1 (8%)
African American 9 (69%)
Age (yrs) 44.3164.63
Education (yrs) 12.4661.81
Nicotine Use 10 (77%)
Cocaine Use
Years of use 18.2365.55
Number of days used last in last 30 days 15.8567.87
Grams/day 1.3060.76
Route of Admin
Smoked 13 (100%)
Data in tables reflect mean 6 S. D.
doi:10.1371/journal.pone.0030854.t001
Table 2. Heart rate and blood pressure during treatment with doxazosin.
Baseline 1 mg 2 mg 3 mg 4 mg
Heart Rate 70.15612.37 75.39613.05 79.38610.28 83.08614.87 83.08610.85
Systolic BP 121.9269.31 124.3967.18 118.39611.91 121.92610.14 124.17612.21
Diastolic BL 79.5467.51 76.9268.08 73.8469.79 77.6969.07 72.0869.86
Cardiovascular measures taken following 3 days of treatment with 1, 2, 3 mg/d of doxazosin and following 1 day of treatment with 4 mg doxazosin. None of the values
differed from baseline (p..05).
doi:10.1371/journal.pone.0030854.t002
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For subjective effects measures, the area under to time-effect
curve (AUC) was calculated using the trapezoidal rule [20]. For
both morning cocaine doses, ratings collected 15 min prior to the
first cocaine dose were used as baseline. For the afternoon dose,
ratings collected 15 min prior to the afternoon cocaine dose were
used as baseline. A two-way repeated measures analysis of
variance (ANOVA) was used to analyze effects of doxazosin (0
and 4 mg) on the subjective effects measured following cocaine at
three dose levels (0, 20, 40 mg). When main effects were
significant, we conducted pairwise multiple comparisons using
the Holm-Sidak method so long as the overall significance level
was p#.05. For cardiovascular measures following cocaine dosing,
repeated measures ANOVA were calculated, with time (pre-dose
to 55 min after cocaine dose) being the repeated measure. We
used a repeated measures analysis for cardiovascular measures
rather than using the AUC approach because the peak values (e.g.
of heart rate and blood pressure) reflect the maximum physiolog-
ical effects of cocaine and we wanted to document how doxazosin
impacted this. We also measured change in cardiovascular
measures following study medication dosing at 8 am by comparing
cardiovascular measures taken at 9 am to those taken prior to
dosing at 7:30 am using a repeated measures ANOVA. The data
were tested for normality using the Shapiro-Wilk normality test,
and for equal variance using the Levene median test. Statistics
were calculated using Sigmaplot version 12 (Systat Software, Inc,
San Jose, CA).
Results
The numbers of participants screened, randomized, and the
sample analyzed are shown in Figure 1. Participants’ demographic
and drug use characteristics are shown in Table 1. Participants
were middle-aged and used cocaine on average for more than a
Table 3. Change in heart rate and blood pressure following dosing.
Doxazosin 1 mg 2 mg 3 mg 4 mg
Heart Rate .61610.1 22.92613.6 6.08612.01 5.0869.81
Systolic BP 2.1568.25 21.4668.38 22.1569.22 2.4668.40
Diastolic BL 21.3864.33 .6968.62 .85612.16 21.15610.53
Placebo
Heart Rate .2369.43 2.54615.40 1.61613.20 22.1569.71
Systolic BP 2.4661035 1.1568.38 21.3868.93 22.31612.24
Diastolic BL 21.0867.67 21.8565.86 22.6966.72 21.3868.98
Study medication was dosed at 8am and values represent change (9am minus 7:30am) in heart rate and blood pressure. Measures recorded during treatment with
doxazosin did not differ from those recorded during treatment with placebo and no dose differed from another dose (p..10).
doi:10.1371/journal.pone.0030854.t003
Figure 2. Heart rate and blood pressure following cocaine dosing. Cardiovascular measures are plotted as change from baseline following
cocaine administration. There were modest, trend-level reductions in systolic blood pressure effects of cocaine during doxazosin treatment. * p,.05,
+ p,.10.
doi:10.1371/journal.pone.0030854.g002
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met criteria for dependence. Most smoked cigarettes and met
criteria for nicotine dependence.
Doxazosin treatment was well tolerated and no participant was
discontinued from the study due to side-effects. No participant
spontaneously reported sedation, a known side effect of doxazosin,
though we did not rate sedation or query participants. Heart rate
and blood pressure were not significantly affected. Heart rate and
blood pressure measures on the final day of treatment with each
doxazosin dose are shown in Table 2. There were no significant
differences between measures taken during placebo and doxazosin
treatment (p..10). Change in heart rate and blood pressure
following study medication dosing on the first day of treatment
with each dose of study medication, when the largest effects would
be expected, are shown in Table 3. Doxazosin and placebo both
produced minimal changes in blood pressure measured following
Figure 3. Heart rate and blood pressure following cocaine dosing. Cardiovascular measures are plotted as change from baseline following
cocaine administration. There were modest, trend-level reductions in systolic blood pressure effects of cocaine during doxazosin treatment. * p,.05,
+ p,.10.
doi:10.1371/journal.pone.0030854.g003
Figure 4. Heart rate and blood pressure following cocaine dosing. Cardiovascular measures are plotted as change from baseline following
cocaine administration. There were modest, trend-level reductions in systolic blood pressure effects of cocaine during doxazosin treatment. * p,.05,
+ p,.10.
doi:10.1371/journal.pone.0030854.g004
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dose of study medication (p..10).
Doxazosin had trend-level effects on systolic blood pressure
following cocaine dosing (p,.09) but did not significantly affect
diasystolic blood pressure or heart rate and there were no
statistically significant interactions between cocaine dose and
cardiovascular measures. Cardiovascular measures over the
55 min following cocaine dosing are shown in Figures 2, 3, 4.
Figure 5. Subjective effects following cocaine dosing. Subjective effects ratings were collected using Likert scales ranging from 0 to 100, with
0 anchored as ‘‘not effects’’ and 100 anchored as ‘‘most ever’’. ANOVA showed that there were significant effects (p,.05) of medication on ratings of
‘‘Stimulated’’, ‘‘Like Cocaine’’, ‘‘Desire Cocaine’’, and ‘‘Likely to Use Cocaine’’. Post hoc analysis showed that the statistically significant effects were
observed following 20 mg cocaine with trend-level effects following 40 mg cocaine. * p,.05, + p,.10.
doi:10.1371/journal.pone.0030854.g005
Figure 6. Subjective effects following cocaine dosing. Subjective effects ratings were collected using Likert scales ranging from 0 to 100, with
0 anchored as ‘‘not effects’’ and 100 anchored as ‘‘most ever’’. ANOVA showed that there were significant effects (p,.05) of medication on ratings of
‘‘Stimulated’’, ‘‘Like Cocaine’’, ‘‘Desire Cocaine’’, and ‘‘Likely to Use Cocaine’’. Post hoc analysis showed that the statistically significant effects were
observed following 20 mg cocaine with trend-level effects following 40 mg cocaine. * p,.05, + p,.10.
doi:10.1371/journal.pone.0030854.g006
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effects, including ‘‘high’’, ‘‘any drug effect’’, ‘‘stimulated’’, and
‘‘good effects’’ (p,.001). There were significant effects of study
drug treatment for ratings of ‘‘stimulated’’ (F=7.41, p=.019),
‘‘like’’ (F=5.17, p=.042), and ‘‘desire cocaine’’ (F=5.47,
p=.037), and ‘‘likely to use cocaine if had access’’ (5.57,
p=.036). For each of these variables, the assumptions regarding
normal distributions of data were met. For all but ‘‘like’’ the equal
variance assumption was met as well. These are shown in figures 5,
6, 7, 8. Post hoc analysis (using the Holm-Sidak method) showed
that doxazosin treatment reduced effects the effects of 20 mg
cocaine on ratings of ‘‘stimulated’’ (t=2.20, p=.035), ‘‘like’’
(t=2.16, p=.037), and ‘‘likely to use cocaine if had access’’
(t=2.29, p=.028). These analyses showed that doxazosin
Figure 7. Subjective effects following cocaine dosing. Subjective effects ratings were collected using Likert scales ranging from 0 to 100, with
0 anchored as ‘‘not effects’’ and 100 anchored as ‘‘most ever’’. ANOVA showed that there were significant effects (p,.05) of medication on ratings of
‘‘Stimulated’’, ‘‘Like Cocaine’’, ‘‘Desire Cocaine’’, and ‘‘Likely to Use Cocaine’’. Post hoc analysis showed that the statistically significant effects were
observed following 20 mg cocaine with trend-level effects following 40 mg cocaine. * p,.05, + p,.10.
doi:10.1371/journal.pone.0030854.g007
Figure 8. Subjective effects following cocaine dosing. Subjective effects ratings were collected using Likert scales ranging from 0 to 100, with
0 anchored as ‘‘not effects’’ and 100 anchored as ‘‘most ever’’. ANOVA showed that there were significant effects (p,.05) of medication on ratings of
‘‘Stimulated’’, ‘‘Like Cocaine’’, ‘‘Desire Cocaine’’, and ‘‘Likely to Use Cocaine’’. Post hoc analysis showed that the statistically significant effects were
observed following 20 mg cocaine with trend-level effects following 40 mg cocaine. * p,.05, + p,.10.
doi:10.1371/journal.pone.0030854.g008
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cocaine on ratings of ‘‘stimulated’’ (t=1.78, p=.083), ‘‘desire
cocaine’’ (t=1.96, p=.059), and ‘‘likely to use cocaine if had
access’’ (t=1.78, p=.083). Doxazosin treatment did not have
significant effects on ratings of ‘‘high’’, ‘‘any drug effects’’ or other
subjective effects ratings (not shown).
Discussion
Doxazosin treatment was well tolerated, as was expected from
earlier studies in other normotensive populations [21]. Doxazosin
treatment had very modest effects on heart rate and blood
pressure. The blood pressure effects of cocaine are likely mediated
by sympathetic outflow and by effects of epinephrine and NE on
peripheral vasculature and the observed effects of doxazosin on the
cardiovascular effects of cocaine are consistent with this.
Doxazosin treatment significantly attenuated several of the
positive subjective effects produced by cocaine, including ratings of
‘‘stimulated’’ and ‘‘like cocaine’’, though the results for like should
be interpreted with caution due to statistical limitations. Doxazosin
also attenuated ratings of ‘‘likely to use’’ an index of craving. The
magnitude of the effect was substantial for some of the variables
(for example, the effect size d for reductions in ‘‘stimulated’’ during
doxazosin treatment following administration of 20 mg cocaine
was 0.84, which is considered large [22]).
The usual dose of doxazosin for the treatment of hypertension is
8–16 mg/d, which is several-fold higher than the dose we tested in
this study, 4 mg/d. Further, though doxazosin 4 mg substantially
attenuated many of the effects produced by 20 mg cocaine, this
dose of doxazosin reduced the effects produced by 40 mg cocaine
to a more modest extent. Higher doses of doxazosin would be
expected to have a greater impact on the effects produced by a
wider range of cocaine doses, including perhaps doses abused by
cocaine users. These doses are thought to be in the 50 to 100 mg
range, though there are no good data to base this estimate on.
Nevertheless, that doxazosin antagonism of cocaine’s was
surmounted by the higher cocaine dose suggests a pharmacolog-
ical dose-effect function and likely higher doses of doxazosin are
needed for more complete antagonism.
These data are very much in keeping with data reported in rats
by Zhang and colleagues [12], who found that prazosin
pretreatment dose-dependently attenuated cocaine-induced rein-
statement of extinguished cocaine-seeking behavior. The ‘‘rein-
statement model’’ is frequently put forward as a model for craving
induced by drug, stress, or other factors [23].
The report by Zhang and colleagues is somewhat at odds with
older data reported by Woolverton [24] who found that prazosin
did not alter responding maintained by cocaine. Prazosin
treatment thus produced differential effects on cocaine reinstate-
ment compared to reinforcing effects of cocaine. Consistent with
this dissociation, we found that doxazosin treatment reduced
indices reflecting desirability of cocaine, such as ‘‘like’’ and ‘‘likely
to use cocaine with access’’, without affecting indices reflecting
euphoria, such as ‘‘high’’. Euphoric effects are thought to relate to
reinforcing effects [25,26], though they need not necessarily do so
[27].
The dampening effects of doxazosin on ratings of ‘‘stimulated’’
that we observed may reflect doxazosin’s specific effects on
noradrenergic neurotransmission. Cocaine inhibits the reuptake of
NE with nearly the same potency that it inhibits the reuptake of
DA [28]. The present data complement earlier preclinical research
[7], and underscore the importance of noradrenergic mechanisms
in mediating many of cocaine’s effects.
It is not known precisely how doxazosin treatment modulates
the subjective effects of cocaine. Noradrenergic a1Rs are expressed
widely throughout the brain, most notably in the striatum and the
prefrontal cortex (PFC) [29]. Acting within the PFC, doxazosin
could block noradrenergically mediated release of DA in the
fronto-accumbens circuit, blunting accumbal activation [30].
These data demonstrate, for the first time in humans, that an
a1R receptor antagonist can attenuate several of the effects of
cocaine. These findings parallel closely those previously reported
in preclinical research, increasing confidence in the findings.
Nevertheless, the sample size was relatively small and replication is
needed. The dose of doxazosin used was at the low end of the
therapeutic window, and higher doses should be tested. Other
medications affecting adrenergic activation are used successfully in
the treatment of hypertension [31] (also a noradrenergically-
mediated phenomenon) and these might be assessed as possible
treatments for cocaine dependence as well. Examples include
other preparations of doxazosin, such as extended release
doxazosin XL, a2R receptor agonists such as lofexidine, and
other classes of antihypertensives, such angiotensin converting
enzyme inhibitors (e.g. perindopril).
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